In published preclinical research, BPC-157 has been administered at doses ranging from 6 to 50 micrograms per kilogram body weight in animal models, with most tissue-repair and gastric-protection protocols using 10 to 20 mcg/kg once or twice daily (PMID 21030672, PMID 32558293, PMID 38980576)
As about 50% of all melanomas show an expression of the BRAFV600E oncogene, one treatment strategy is based on the development of specific BRAFV600E inhibitors
In the TRIUMPH-4 Phase 3 trial, the most common adverse events for the 12 mg dose were nausea (43.2%), diarrhea (33.1%), constipation (25.0%), vomiting (20.9%), and decreased appetite
Constant nausea and abdominal pain is an unpleasant reality
Healthy veins have one-way valves that push blood upward toward your heart against gravity
Galactomyces face masks offer multiple benefits including improved skin texture, enhanced brightness, and better overall clarity